Presentation is loading. Please wait.

Presentation is loading. Please wait.

EFFECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS ON MORTALITY, CARDIOVASCULAR HOSPITALIZATION AND FUNCTIONAL CAPACITY IN PATIENTS WITH HEART.

Published byMartin Brodersen Modified over 5 years ago

Similar presentations

Presentation on theme: "EFFECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS ON MORTALITY, CARDIOVASCULAR HOSPITALIZATION AND FUNCTIONAL CAPACITY IN PATIENTS WITH HEART."— Presentation transcript:

1 EFFECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS ON MORTALITY, CARDIOVASCULAR HOSPITALIZATION AND FUNCTIONAL CAPACITY IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS  A. Alshahrani, G.A. Wells, P. Liu  Canadian Journal of Cardiology  Volume 31, Issue 10, (October 2015) DOI: /j.cjca Copyright © Terms and Conditions

2 Canadian Journal of Cardiology 2015 31, DOI: (10. 1016/j. cjca. 2015
Copyright © Terms and Conditions

Download ppt "EFFECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS ON MORTALITY, CARDIOVASCULAR HOSPITALIZATION AND FUNCTIONAL CAPACITY IN PATIENTS WITH HEART."

Similar presentations

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.
Sex- and Gender-Related Risk Factor Burden in Patients With Premature Acute Coronary Syndrome Jin Choi, MSc, Stella Styliani Daskalopoulou, MD, MSc, PhD,

Sex- and Gender-Related Risk Factor Burden in Patients With Premature Acute Coronary Syndrome Jin Choi, MSc, Stella Styliani Daskalopoulou, MD, MSc, PhD,
PLATELET REACTIVITY, P2Y12 RECEPTOR INHIBITOR SELECTION AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH PERCUTANEOUS.

PLATELET REACTIVITY, P2Y12 RECEPTOR INHIBITOR SELECTION AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH PERCUTANEOUS.
DOES IT MATTER WHICH SURGEON WORKS WITH WHICH ASSISTANT

DOES IT MATTER WHICH SURGEON WORKS WITH WHICH ASSISTANT
Kiran Sidhu, MD, FRCPC, Anthony Tang, MD, FRCPC 

Kiran Sidhu, MD, FRCPC, Anthony Tang, MD, FRCPC 
Anticoagulation Regimens During Pregnancy in Patients With Mechanical Heart Valves: A Systematic Review and Meta-analysis  Zhe Xu, MD, PhD, Jin Fan, MD,

Anticoagulation Regimens During Pregnancy in Patients With Mechanical Heart Valves: A Systematic Review and Meta-analysis  Zhe Xu, MD, PhD, Jin Fan, MD,
HOMOGRAFT VERSUS CONVENTIONAL PROSTHESIS FOR SURGICAL MANAGEMENT OF AORTIC VALVE INFECTIVE ENDOCARDITIS A SYSTEMATIC REVIEW AND META-ANALYSIS  B. Yanagawa,

HOMOGRAFT VERSUS CONVENTIONAL PROSTHESIS FOR SURGICAL MANAGEMENT OF AORTIC VALVE INFECTIVE ENDOCARDITIS A SYSTEMATIC REVIEW AND META-ANALYSIS  B. Yanagawa,
IS RIGHT HEART FUNCTION ADVERSELY AFFECTED IN BREAST CANCER PATIENTS UNDERGOING ANTHRACYCLINE-BASED CHEMOTHERAPY?  K.E. Boczar, I. Al-Harbi, J. Sulpher,

IS RIGHT HEART FUNCTION ADVERSELY AFFECTED IN BREAST CANCER PATIENTS UNDERGOING ANTHRACYCLINE-BASED CHEMOTHERAPY?  K.E. Boczar, I. Al-Harbi, J. Sulpher,
904 Hypertension Analysis of Stress Reduction Using Mindfulness Meditation and Yoga: Results From a Randomized Controlled Trial  K. Blom, B. Baker, M.

904 Hypertension Analysis of Stress Reduction Using Mindfulness Meditation and Yoga: Results From a Randomized Controlled Trial  K. Blom, B. Baker, M.
ISCHEMIC AND BLEEDING EVENTS IN CANADIAN PATIENTS WITH MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WHO REQUIRE ORAL ANTICOAGULATION:

ISCHEMIC AND BLEEDING EVENTS IN CANADIAN PATIENTS WITH MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WHO REQUIRE ORAL ANTICOAGULATION:
Robert Roberts, MD, FRCPC, MACC  Canadian Journal of Cardiology 

Robert Roberts, MD, FRCPC, MACC  Canadian Journal of Cardiology 
273 Bivalirudin Versus Heparin-Monotherapy in All Comers After Percutaneous Intervention: The Québec Heart-Lung Institute Experience  J. MacHaalany, E.

273 Bivalirudin Versus Heparin-Monotherapy in All Comers After Percutaneous Intervention: The Québec Heart-Lung Institute Experience  J. MacHaalany, E.
171 The risk stratification and stroke prevention therapy care gap in canadian atrial fibrillation patients: Insights from the Facilitating Review and.

171 The risk stratification and stroke prevention therapy care gap in canadian atrial fibrillation patients: Insights from the Facilitating Review and.
CONTRIBUTION OF AORTIC REGURGITATION TO LEFT VENTRICLE LOAD IN PATIENTS WITH AORTIC STENOSIS: A MATHEMATICAL MODEL ANALYSIS  A. Djebbari, W. Mawad, N.

CONTRIBUTION OF AORTIC REGURGITATION TO LEFT VENTRICLE LOAD IN PATIENTS WITH AORTIC STENOSIS: A MATHEMATICAL MODEL ANALYSIS  A. Djebbari, W. Mawad, N.
MODERATE/SEVERE DIASTOLIC DYSFUNCTION IS ASSOCIATED WITH WORSE OUTCOME IN PATIENTS WITH LOW-FLOW, LOW-GRADIENT AORTIC STENOSIS AND LOW EJECTION FRACTION.

MODERATE/SEVERE DIASTOLIC DYSFUNCTION IS ASSOCIATED WITH WORSE OUTCOME IN PATIENTS WITH LOW-FLOW, LOW-GRADIENT AORTIC STENOSIS AND LOW EJECTION FRACTION.
The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence  David D. Waters, MD, Sripal Bangalore, MD,

The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence  David D. Waters, MD, Sripal Bangalore, MD,
The use of Intravenous Iron Therapy in Iron Deficient Patients with Heart Failure with Reduced Ejection Fraction: Decrease Hospitalizations and Improve.

The use of Intravenous Iron Therapy in Iron Deficient Patients with Heart Failure with Reduced Ejection Fraction: Decrease Hospitalizations and Improve.
166 Correlation Between Cytochrome P450 2C19 Enzymatic Activity Assessed by [13C]-Pantoprazole Breath Test and Platelet Reactivity in Patients Treated.

166 Correlation Between Cytochrome P450 2C19 Enzymatic Activity Assessed by [13C]-Pantoprazole Breath Test and Platelet Reactivity in Patients Treated.
EMPA-REG OUTCOME: The Endocrinologist's Point of View

EMPA-REG OUTCOME: The Endocrinologist's Point of View
EMPA-REG OUTCOME: The Endocrinologist's Point of View

EMPA-REG OUTCOME: The Endocrinologist's Point of View

Similar presentations

Ads by Google